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erve growth factor (NGF) mediates the survival and
differentiation of neurons by stimulating the tyrosine
kinase activity of the TrkA/NGF receptor. Here, we
identify SHP-1 as a phosphotyrosine phosphatase that neg-
atively regulates TrkA. SHP-1 formed complexes with TrkA
at Y490, and dephosphorylated it at Y674/675. Expression
of SHP-1 in sympathetic neurons induced apoptosis and TrkA
dephosphorylation. Conversely, inhibition of endogenous
SHP-1 with a dominant-inhibitory mutant stimulated basal
tyrosine phosphorylation of TrkA, thereby promoting NGF-
independent survival and causing sustained and elevated
N
 
TrkA activation in the presence of NGF. Mice lacking SHP-1
had increased numbers of sympathetic neurons during the
period of naturally occurring neuronal cell death, and
when cultured, these neurons survived better than wild-
type neurons in the absence of NGF. These data indicate
that SHP-1 can function as a TrkA phosphatase, controlling
both the basal and NGF-regulated level of TrkA activity in
neurons, and suggest that SHP-1 regulates neuron number
during the developmental cell death period by directly
regulating TrkA activity.
 
Introduction
 
The survival of cells of the nervous system is dependent on
the action of neurotrophic factors that prevent both intrinsic
and extrinsic cues from inducing cellular apoptosis. In devel-
oping peripheral neurons, neurotrophic target-derived factors,
such as NGF, retrogradely determine neuronal survival by
suppressing autocrine and p75
 
NTR
 
-induced apoptotic signals.
This interplay between life and death signals precisely regu-
lates neuron number during development. The initial step in
NGF survival signaling is the stimulation of the tyrosine
kinase activity of the NGF receptor, TrkA, which in turn
activates key survival and axonal growth regulatory proteins
such as PI 3-kinase, Akt, and MEK/MAPK (Kaplan and
Miller, 2000; Patapoutian and Reichardt, 2001). The acti-
vated survival proteins suppress the activity of apoptotic
proteins such as Bad, Forkhead, p53, and BAX (Datta et al.,
1999; Mazzoni et al., 1999), and increase the levels and
activities of pro-survival proteins such as CREB, Bcl-2, and
 
 
 
Np73 (Riccio et al., 1999; Pozniak et al., 2000). NGF-
activated TrkA initiates survival signaling by binding to and
phosphorylating on tyrosine proteins such as Shc, FRS-2,
rAPS, and SH2-B that activate the Ras–PI 3-kinase and
Ras–MAPK signaling pathways and PLC-
 
 
 
1, which regu-
lates protein kinase C activity and intracellular calcium lev-
els (Kaplan and Miller, 2000; Patapoutian and Reichardt,
2001). The major sites whereby Trk associates with and couples
to intracellular signaling pathways in primary neurons are
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the SHC/FRS-2 and the PLC-
 
 
 
1 binding sites, Y490 and
Y785, respectively (Atwal et al., 2000). Although TrkA func-
tions by phosphorylating on tyrosine and thereby activating
signaling proteins involved in neuronal survival and differen-
tiation, paradoxically, it also activates the phosphotyrosine
(pTyr) phosphatase SHP-1 (Vambutas et al., 1995). Because
phosphatases such as SHP-1 can have both positive and neg-
ative effects on receptor tyrosine kinase signaling (Tonks and
Neel, 2001), we asked about the function and mechanism of
action of this protein in NGF signal transduction.
The SHP family of protein tyrosine phosphatases includes
SHP-1, SHP-2, and the 
 
Drosophila
 
 
 
melanogaster
 
 homologue
Corkscrew (Tonks and Neel, 2001). SHP-1 is expressed in
the hematopoietic system, the nervous system, epithelial
cells, and the NGF-responsive PC12 cell line (Tonks and
Neel, 2001). The 
 
motheaten
 
 (
 
me/me
 
) mouse, which lacks
SHP-1 expression, displays an array of hematopoietic abnor-
malities resulting in severe immunodeficiency and systemic
autoimmunity (Tsui and Tsui, 1994). The pathology of the
 
me/me
 
 mouse, which is caused by the overproduction of
multiple hematopoietic cell lineages, initially suggested that
SHP-1 was primarily a negative regulator of cell prolifera-
tion. In this regard, SHP-1 has been shown to interact with
and dephosphorylate a number of growth factor receptors,
including those for insulin-like growth factor-1, platelet-
derived growth factor, EGF (Tonks and Neel, 2001), and
Ros (Keilhack et al., 2001). In contrast, SHP-1, like SHP-2,
has been shown to positively regulate MAPK signaling
(Krautwald et al., 1996; Wright et al., 1997), as well as EGF,
interferon-
 
 
 
, and Ras signaling (Su et al., 1996; You and
Zhao, 1997). The positive effects of SHP-1 signaling may
explain why the absence of SHP-1 in 
 
me/me
 
 mice leads to
decreased numbers of central nervous system glia (Wish-
camper et al., 2001).
Whereas the survival and growth-promoting aspects of
neurotrophin signaling are dependent on the levels of TrkA
receptor autophosphorylation initiated by NGF binding; the
existence of phosphatases that dephosphorylate TrkA would
suggest an additional and important mechanism of neu-
rotrophin receptor regulation. In this regard, our previous
work in PC12 cells showed that SHP-1 was activated after
NGF treatment of PC12 cells (Vambutas et al., 1995).
Here, we have asked about the biological importance of this
activation in two cell types that require TrkA signaling for
their survival, developing sympathetic neurons, and PC12
cells (Greene and Tischler, 1976; Chun and Patterson,
1977). Our results indicate that SHP-1 functions as a TrkA
phosphatase, controlling the level of TrkA activity in cul-
tured neurons and PC12 cells and regulating the number of
NGF-dependent sympathetic neurons during development.
 
Results
 
SHP-1 is expressed in developing sympathetic neurons 
in culture and in vivo
 
SHP-1 expression has not been reported in the peripheral
nervous system. To determine this, we cultured sympathetic
neurons from postnatal day (P) 1 rat superior cervical gan-
glia (SCG), and assessed expression of SHP-1 by Western
blot analysis with an antibody that does not recognize the re-
lated SHP-2 (Tomic et al., 1995). SHP-1 protein was de-
tected in sympathetic neurons, and in Jurkat and PC12 cells
known to express SHP-1 (Vambutas et al., 1995; Fig. 1 A).
SHP-1 was also detected in freshly dissociated P15 mouse
SCGs from wild-type (wt) mice but not from 
 
me/me
 
 mice,
which are genetically deficient in SHP-1 (Fig. 1 B). A devel-
opmental time course revealed that SHP-1 levels remained
constant in the SCG over the period of naturally occurring
cell death from E17 to P10 (Fig. 1 C). Both endogenous
SHP-1 and SHP-1, overexpressed using a recombinant ade-
novirus (Ad), were located predominantly in the cell bodies
of sympathetic neurons (Fig. 2). The neuronal localization
of SHP-1 was confirmed by costaining with the neuronal
marker neurofilament. Therefore, we used sympathetic neu-
rons and PC12 cells to assess SHP-1’s function in NGF sig-
nal transduction.
 
Identification of sites on TrkA that regulate complex 
formation with and are dephosphorylated by SHP-1
 
Previously, we showed that in response to NGF-treatment of
PC12 cells, SHP-1 was activated and formed complexes with
TrkA in vitro (Vambutas et al., 1995). Therefore, we asked
whether SHP-1 and TrkA would form complexes in NGF-
treated PC12 cells and sympathetic neurons. PC12 cells
Figure 1. SHP-1 is expressed in sympathetic neurons. (A) SHP-1 
expression in cultured sympathetic neurons. Cell lysates were prepared 
from Jurkat, PC12 cells, and sympathetic neurons. Sympathetic 
neurons were grown for 5 d in the presence of 20 ng/ml NGF before 
harvesting. 25  g Jurkat, 100  g PC12, and 100  g of sympathetic 
neuron lysates were electrophoresed and probed in Western blots 
with monoclonal anti–SHP-1. (B and C) SHP-1 expression in the 
SCG. Lysates containing equivalent amounts of protein were prepared 
from SCG dissected from (B) mice that lack SHP-1 expression 
(me/me) or wild-type (wt/wt) mice at P15, or (C) from wt mice at 
E17, E19, P1, and P10. Western blot analysis was performed using 
anti–SHP-1. Equal loading of protein was confirmed by reprobing 
the blot in B with antitubulin and in C with anti-Erk1/2 (B and C, 
bottom blots). 
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overexpressing TrkA (clone 6-24; Hempstead et al., 1992) or
sympathetic neurons were treated with NGF, and TrkA pro-
tein was immunoprecipitated with anti-Trk and subjected to
Western blotting with anti–SHP-1. SHP-1 coimmunopre-
cipitated with TrkA from NGF-treated PC12 cells (Fig. 3
A), although this was much more evident in PC12 cells and
sympathetic neurons overexpressing SHP-1 via recombinant
Ad (Fig. 3, B–D). In both PC12 cells and sympathetic neu-
rons, NGF treatment for 5–10 min enhanced complex for-
mation between SHP-1 and TrkA (Fig. 3, B and D).
Next, we identified a site on TrkA that regulates SHP-1
complex formation. To determine this, we used a panel of
TrkA proteins encoding mutations in the two primary bind-
ing sites for TrkA substrates, Y490 (Shc/FRS2 site) and
Y785 (PLC-
 
 
 
1 site) expressed via baculovirus in Sf9 cells
(Stephens et al., 1994). The baculovirus-expressed TrkA was
washed and phosphorylated on Y490 and/or Y785 in vitro,
and was incubated with PC12 cell lysates expressing SHP-1.
TrkA was immunoprecipitated from these lysates with anti-
TrkA; SHP-1 present in the complexes was detected by
Western blotting (Fig. 4 A). SHP-1 formed complexes with
wt TrkA, with TrkA lacking Y785 (Y785F), and to a much
lesser extent, with TrkA lacking Y490 (Y490F and Y490/
785F) or kinase-inactive TrkA (K538N; Fig. 4 A). Thus,
phosphorylated Y490 of TrkA is required for optimal com-
plex formation between SHP-1 with TrkA.
Having defined a site regulating complex formation of
TrkA and SHP-1, we asked whether SHP-1 dephosphory-
lated TrkA in vitro. 
 
32
 
P-labeled TrkA was incubated in vitro
with purified SHP-1. We observed that SHP-1 efficiently
dephosphorylated TrkA (Fig. 4 B). Next, we asked whether
SHP-1 could dephosphorylate TrkA in vivo and identify the
sites of dephosphorylation. TrkA was coexpressed with
SHP-1 in Sf9 cells, and the sites of TrkA dephosphorylation
were determined by Western blotting with antibodies that
recognize phosphorylated Y490 or Y674 and Y675 (Segal et
al., 1996), the latter being sites critical for regulating the
overall catalytic activity of the receptor (Cunningham et al.,
1997). As a control, we coexpressed TrkA with SHP-2.
TrkA expressed in Sf9 cells was constitutively tyrosine phos-
phorylated (Fig. 4 C), as we have previously reported (Ste-
phens et al., 1994). SHP-1 efficiently dephosphorylated
Figure 2. Immunocytochemistry of SHP-1 
expressed in sympathetic neurons. Neurons 
from newborn rat SCGs were cultured in NGF 
and processed for double-label immuno-
cytochemistry using antineurofilament (anti-NF; 
B and E) or anti–SHP-1 (C and F). A–C are 
photomicrographs of the same field of control 
neurons, whereas D–F are of the same field of 
neurons infected with SHP-1–expressing 
recombinant adenovirus for 24 h. arrows, Cells 
overexpressing SHP-1. A, D, and G are phase-
contrast images. In G–I, the primary antibody 
was omitted.
Figure 3. SHP-1 coimmunoprecipitates with TrkA in PC12 cells 
and sympathetic neurons. (A) PC12 cells treated with 50 ng/ml NGF 
for the indicated times were lysed and immunoprecipitated with 
anti-Trk, and precipitated proteins were probed in Western blots 
with anti–SHP-1 (top), anti-pTyr (middle), or anti-Trk (bottom) to 
detect Trk protein levels in the immunoprecipitates. (B) PC12 cells 
were infected with Ad SHP-1 for 24 h, and treated for 5 min with 
NGF before immunoprecipitation with anti-Trk and Western blotting 
with anti–SHP-1 (top) or anti-Trk (bottom). (C) Sympathetic neurons, 
either mock infected or infected with wild-type Ad SHP-1 at the 
indicated MOI, were treated with 50 ng/ml NGF for 10 min. Cells 
were lysed, the lysates were immunoprecipitated with anti-TrkA, 
and immunoprecipitated proteins were subjected to Western blotting 
with anti–SHP-1 (top) or anti-Trk (bottom). (D) Sympathetic neurons 
infected with Ad SHP-1 at the indicated MOIs were treated with 
NGF for 10 min, and cell lysates were immunoprecipitated with 
anti-Trk and probed in Western blots with anti–SHP-1 (top) or 
anti-TrkA (bottom). 
1002 The Journal of Cell Biology 
 
|
 
 
 
Volume 163, Number 5, 2003
 
TrkA at sites Y674/Y675, but only partially dephosphory-
lated TrkA at the Y490 site (Fig. 4 C). SHP-2 was unable to
substantially dephosphorylate either site under these condi-
tions, even though SHP-2 was able to dephosphorylate ex-
ogenous substrates other than TrkA (unpublished data).
Therefore, SHP-1 can dephosphorylate TrkA on specific ty-
rosine residues required for optimal activity.
 
SHP-1 overexpression suppresses the survival of 
sympathetic neurons and PC12 cells
 
The biochemical data indicate that SHP-1 negatively regu-
lates TrkA tyrosine phosphorylation and activation. To de-
termine whether this has functional consequences, we exam-
ined sympathetic neurons that require TrkA signaling for
survival. Neurons were infected with Ad SHP-1 or a domi-
nant-inhibitory SHP-1 mutant (SHP-1
 
 
 
P; Neel and Tonks,
1997), and after 2 d, they were switched into media with or
without 20 ng/ml NGF. After 72 h, survival was quantified
using MTT, which measures mitochondrial function (Man-
thorpe et al., 1986; Fig. 5 A). SHP-1WT expression de-
creased sympathetic neuron survival by 70% (100 multiplic-
ity of infection [MOI]), whereas SHP-1
 
 
 
P expression had
little effect on survival in 20 ng/ml NGF relative to a LacZ-
expressing control virus (Fig. 5 A). The specificity of the
SHP-1 effect was demonstrated by coinfecting neurons with
the Ad SHP-1
 
 
 
P; this completely rescued neurons from
SHP-1WT–induced death (Fig. 5 A). Similarly, coexpres-
sion of Bcl-xL, a protein that prevents NGF withdrawal-
induced apoptosis of sympathetic neurons (Gonzalez-Garcia
et al., 1995), prevented SHP-1WT–mediated suppression of
neuronal survival. The expression of Ad SHP-1 proteins in
sympathetic neurons was confirmed by Western blot analy-
sis with anti–SHP-1 (Fig. 5 B).
To determine whether SHP-1 induced the apoptosis of
sympathetic neurons, we examined the cells by TUNEL
(Fig. 5 C). Approximately 85% of SHP-1WT (200 MOI)–
infected sympathetic neurons were TUNEL positive, con-
firming the results obtained by MTT assay (Fig. 5 D). Un-
infected sympathetic neurons maintained in 20 ng/ml NGF
had few TUNEL-positive cells (
 
 
 
5%), whereas neurons de-
prived of NGF for 48 h were 95% TUNEL positive. Ap-
proximately 12% of the neurons infected with the Ad SHP-
1
 
 
 
P (200 MOI) were TUNEL positive, similar to neurons
infected with Ad LacZ (7% positive; Fig. 5 D). Cell death
was also accompanied by neurite fragmentation (unpub-
lished data). Thus, overexpression of SHP-1 causes apopto-
sis of NGF-dependent sympathetic neurons in culture.
We turned to PC12 cells, whose survival can be promoted
either by NGF or by serum factors such as IGF-1 (Greene
and Tischler, 1976), to find out whether this suppressive ef-
fect of SHP-1 was specific for TrkA-mediated survival.
PC12 cells were infected with Ad SHP-1WT, and cultured
in serum or in NGF without serum for 72 h. MTT analysis
demonstrated that overexpression of SHP-1WT decreased
survival of PC12 cells maintained in NGF by 50% (100
MOI; Fig. 6 A), but had no effect on PC12 cells maintained
in serum (Fig. 6 B). Thus, SHP-1 is specific for TrkA-medi-
ated survival, and does not apparently inhibit survival pro-
moted by other exogenous factors present in serum. Based
on these results, together with the biochemical analysis, we
hypothesized that SHP-1 directly inhibited TrkA and TrkA-
mediated downstream survival signals.
 
SHP-1 dephosphorylates TrkA in PC12 cells and 
sympathetic neurons
 
To determine if SHP-1 could dephosphorylate TrkA in
PC12 cells and sympathetic neurons as we had hypothe-
sized, the cells were infected with Ad SHP-1WT or, as con-
trols, Ad SHP-2 or Ad LacZ (Fig. 6 C). Cells were exposed
to NGF for 5 min, and the levels of TrkA tyrosine phos-
phorylation were assessed by anti-TrkA immunoprecipita-
tions followed by Western blotting with anti-pTyr (Fig. 6,
D and E). This analysis revealed that, as seen in Sf9 cells,
Figure 4. SHP-1 forms complexes with TrkA at Y490 and dephos-
phorylates TrkA in Sf9 cells at Y674/Y675 and in vitro. (A) WT 
TrkA, but not TrkA mutated at Y490, forms complexes with SHP-1 in 
vitro. Human TrkA expressed in Sf9 cells was immunoprecipitated, 
subjected to autophosphorylation in vitro, and incubated with PC12 
cell lysates as a source of SHP-1. TrkA-containing immune complexes 
were washed extensively and probed on Western blots with anti–
SHP-1. The TrkA receptors were WT TrkA, Flag epitope-tagged WT 
TrkA (Flag TrkA), or receptors encoding mutations at Y490 (Y490F), 
Y785 (Y785F), Y490 and Y785 (Y490/785F), or K538 (K538N), a 
kinase inactive form of TrkA. The control lane has no input TrkA 
protein. The blot was reprobed with anti-Trk to show that similar 
amounts of Trk protein were present in each lane. (B) SHP-1 dephos-
phorylates TrkA in vitro. SHP-1 or TrkA were expressed in Sf9 cells, 
and immunoprecipitated with anti–SHP-1 or anti-Trk. The purified 
TrkA was autophosphorylated with 
32P-labeled ATP in vitro and 
incubated with or without immunopurified SHP-1, and the reaction 
products were electrophoresed and exposed to film. The blot was re-
probed with anti-Trk to show equivalent levels of TrkA in each lane. 
(C) SHP-1 dephosphorylates TrkA in vivo at Y674 and Y675. WT 
TrkA was expressed with SHP-1 or SHP-2 in Sf9 cells, and TrkA 
phosphorylation levels were assessed by Western blots using anti-
phosphorylated Y490 Trk (p490, top right) and antiphosphorylated 
Y674/675 Trk (p674/675, top left). The blots were reprobed with 
anti-TrkA (second panels), anti–SHP-1 (third panels), and anti–SHP-2 
(bottom panels) to indicate the levels of each of these proteins. 
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SHP-1 overexpression completely blocked the ability of
NGF to stimulate TrkA tyrosine phosphorylation in both
PC12 cells (Fig. 6 D) and sympathetic neurons (Fig. 6 E). In
contrast, neither SHP-2 nor LacZ expression had any detect-
able effect. These results were confirmed by performing sim-
ilar experiments and probing the Western blots with an-
tiphospho-Y674/Y675 Trk (Fig. 6 F); this analysis indicated
that dephosphorylation of TrkA occurred at these two sites
in sympathetic neurons as it had in Sf9 cells. These results
suggest that a potential mechanism used by SHP-1 to cause
cell death is dephosphorylating TrkA.
 
SHP-1 decreases the activity of NGF-stimulated 
signaling proteins
 
We first examined NGF-induced changes in tyrosine phos-
phorylation, to determine how overexpression of SHP-1 af-
fects NGF-mediated TrkA survival signals. Sympathetic neu-
rons were infected with Ad SHP-1WT, washed free of NGF,
and then treated for 5 min with 100 ng/ml NGF. Western
blot analysis with anti-pTyr revealed that SHP-1WT had lit-
tle effect on overall basal tyrosine phosphorylation, but that
it suppressed the tyrosine phosphorylation of NGF-stimu-
lated signaling proteins (Fig. 7 A). Particularly evident was
the decreased phosphorylation of two bands that migrated at
the molecular weight of the MAPKs, Erk1, and Erk2.
To find whether SHP-1 overexpression specifically inhib-
ited downstream TrkA signaling pathways, we examined tyro-
sine phosphorylation of PLC-
 
 
 
1, a direct TrkA substrate
(Kaplan and Miller, 2000; Fig. 7 B), and the phosphorylation
of Akt (Fig. 7 C), which occurs after NGF treatment of sym-
pathetic neurons and which regulates NGF-dependent cell
survival (Kaplan and Miller, 2000). Neurons were infected
and treated with NGF, and lysates were immunoprecipitated
with anti–PLC-
 
 
 
1 and probed with anti-pTyr (Fig. 7 B), or
were analyzed by Western blots with anti–phospho-S473 Akt
(Fig. 7 C). This analysis revealed that SHP-1 overexpression
inhibited NGF-mediated phosphorylation of both of these
downstream TrkA targets. Thus, SHP-1 is a potent inhibitor
of multiple TrkA-activated signaling proteins, suggesting that
it exerts its effects at the level of the receptor itself.
Finally, we examined whether overexpression of SHP-1 re-
sulted in the activation of cell death–inducing proteins, as
would be predicted if it induces apoptosis by suppressing Trk
signaling. Two such proteins that are induced or activated by
Figure 5. SHP-1 overexpression suppresses 
the survival of cultured sympathetic neurons. 
(A) MTT survival assays of sympathetic neurons 
infected with various MOIs of adenovirus 
encoding SHP-1WT, SHP-1 P (dominant-
negative), BCl-XL (pro-survival protein), or 
LacZ (control virus) in the presence of NGF. 
In brief, neurons were grown in 20 ng/ml NGF 
for 5 d, infected with the indicated Ad, and 48 h 
later, assayed for survival by MTT assay. Values 
were normalized to that of 20 ng/ml NGF 
(100% survival). (B) Western blot analysis of 
equivalent amounts of protein from sympathetic 
neurons infected with Ad SHP-1WT or Ad 
SHP-1 P. NGF-selected sympathetic neurons 
were infected with Ad for 48 h at 50 MOI. 
Neurons were lysed, and equal amounts of 
protein were electrophoresed and probed in 
Western blots with anti–SHP-1. (C) TUNEL of 
sympathetic neurons transduced with Ad 
SHP-1WT. Cultured sympathetic neurons were 
either mock infected (top four panels) or infected 
with 200 MOI of Ad SHP-1WT or Ad LacZ, and 
were maintained in 20 ng/ml NGF for 48 h 
before TUNEL and Hoechst labeling to detect 
all of the nuclei in the field. Each set of two 
panels represents the same field photographed 
under one set of fluorescence filters for Hoechst 
(left) and a second set for TUNEL (right). Neurons 
deprived of NGF for 48 h were included as a 
control ( NGF). (D) Quantification of TUNEL 
data is similar to that shown in C. Error bars 
represent the SEM. 
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Figure 6. SHP-1 inhibits NGF-induced, but 
not serum-induced, survival of PC12 cells and 
dephosphorylates TrKA in PC12 and neurons. 
(A and B) MTT survival assays of PC12 cells 
infected with Ad SHP-1WT or Ad LacZ at the 
indicated MOIs. Cells were washed free of 
serum and incubated in the absence (A) or 
presence (B) of serum, and in the presence or 
absence of NGF as indicated. 48 h later, MTT 
assays were performed and the data were nor-
malized to survival induced by 20 ng/ml NGF 
or serum. Ad SHP-1 suppressed NGF-induced, 
but not serum-induced, survival. (C–F) SHP-1 
dephosphorylates NGF-activated TrkA in PC12 
cells and sympathetic neurons. (C) Western 
blot analysis with anti–SHP-1 to determine the 
levels of SHP-1 expression in PC12 cells infected 
with Ad SHP-1WT. (D–F) PC12 cells (D) or 
sympathetic neurons (E and F) were established 
in 20 ng/ml NGF and were infected with Ad 
SHP-1WT, SHP-2, or LacZ at the indicated 
MOIs. Cells were washed free of NGF and 
exposed to 100 ng/ml NGF for 5 min. TrkA was 
immunoprecipitated and subjected to Western 
blot analysis (D and E) with anti-pTyr to assess 
tyrosine phosphorylation, or (F) with antibodies 
specific to phosphorylated residues Y674/Y675 
of Trk (p674/5Trk). In all experiments, the blots 
were reprobed with anti-Trk to detect TrkA 
protein levels in the immunoprecipitates.
Figure 7. SHP-1 inhibits NGF-induced phos-
phorylation of MAPK/Erk, PLC- 1, and Akt, 
and increases Bim/Bod expression and c-jun 
phosphorylation. Sympathetic neurons grown 
in 20 ng/ml NGF were infected with Ad SHP-
1WT or LacZ, washed free of NGF, and treated 
for 5 min with 100 ng/ml NGF. (A) Western 
blot analysis for total tyrosine-phosphorylated 
proteins in lysates of neurons infected with 
Ad SHP-1WT at an MOI of 25 (which induced 
50% cell death in this experiment) or of 50 
(which induced 75% cell death; top panel). 
The positions of proteins migrating at the 
molecular weights of SHP-1 and MAPK (Erk1/2) 
are indicated. The blots were reprobed with 
anti–SHP-1 (bottom panel) to show the levels of 
recombinant protein expressed in each sample. 
(B) Ad SHP-1WT suppresses PLC- 1 tyrosine 
phosphorylation. Neurons infected with Ad 
SHP-1WT or LacZ were treated with 100 ng/ml 
NGF, and PLC- 1 was immunoprecipitated 
from the lysates. NGF-induced tyrosine phos-
phorylation of PLC- 1 was determined by 
probing Western blots of the precipitates with 
anti-pTyr (top). The blot was reprobed with 
anti–PLC- 1 to indicate PLC- 1 levels in each 
lane (bottom). (C) Ad SHP-1WT suppresses Akt 
phosphorylation. Neurons were infected with 
Ad SHP-1WT at various MOIs, induced with 
100 ng/ml NGF for 5 min, and the phosphory-
lation of Akt was determined by probing Western blots with antiphosphorylation-specific Akt directed at S473 (top). The level of Akt in each 
lane was determined by reprobing with anti-Akt (bottom). (D) Ad SHP-1 increases the levels of Bim/Bod and the phosphorylation of c-jun, 
and suppresses the phosphorylation of Erk1/2. Ad SHP-1WT did not alter the levels of p75
NTR or XIAP. Neurons were infected with Ad SHP-1WT 
or Ad LacZ at 200 MOI in the presence of 20 ng/ml NGF, and equivalent amounts of protein from cell lysates were examined using antibodies 
to the indicated proteins in Western blots. 
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the lack of TrkA signaling are c-jun and Bim/Bod (Putcha et
al., 2001; Whitfield et al., 2001). Western blot analysis of
sympathetic neurons expressing SHP-1WT, and maintained
in 20 ng/ml NGF, showed that SHP-1 overexpression
caused increased levels of Bim/Bod and the phosphorylation
(activation) of c-jun (Fig. 7 D), coincident with a decrease in
Erk1/2 phosphorylation. In contrast, the levels of the p75
 
NTR
 
and the pro-survival protein XIAP (Wiese et al., 1999) were
not affected by SHP-1 overexpression (Fig. 7 D).
 
Inhibition of endogenous SHP-1 rescues sympathetic 
neurons and PC12 cells from NGF withdrawal 
by increasing basal TrkA activation
 
These data indicate that overexpression of SHP-1 acts to de-
crease TrkA tyrosine phosphorylation, resulting in decreased
downstream survival signals and subsequent neuronal apopto-
sis. To ask whether endogenous SHP-1 plays a similar role in
regulating TrkA activity, we used the dominant-inhibitory
mutant SHP-1
 
 
 
P. Sympathetic neurons were cultured for
4 d, infected with Ad SHP-1
 
 
 
P or LacZ, and either withdrawn
from NGF or treated with 10 ng/ml NGF. In the absence of
NGF, SHP-1
 
 
 
P expression maintained the survival of 50%
of the neurons, whereas survival of LacZ-infected neurons was
similar to controls (Fig. 8 A). Similar results were obtained us-
ing PC12 cells (Fig. 8 B, left). PC12 cells maintained in se-
rum were infected for 24 h with the SHP-1
 
 
 
P virus at various
MOIs. After infection, the cells were washed free of serum
and cell survival was assessed after 72 h using MTT (Man-
thorpe et al., 1986). Expression of SHP-1
 
 
 
P increased PC12
cell survival in the absence of serum or NGF in a dose-depen-
dent manner (Fig. 8 B, left). Survival with 50 MOI of SHP-
1
 
 
 
P was 50% of that seen with 50 ng/ml NGF.
The enhanced survival seen with SHP-1
 
 
 
P in the absence
of NGF could be due to increased ligand-independent basal
Figure 8. Inhibition of endogenous SHP-1 enhances 
TrkA survival signaling and rescues sympathetic neurons 
and PC12 cells from death induced by NGF withdrawal. 
(A) Dominant-negative Ad SHP-1 P rescues sympathetic 
neurons from NGF withdrawal-induced cell death. 
Sympathetic neurons cultured for 5 d in 20 ng/ml NGF 
were infected with Ad SHP-1 P or LacZ. 48 h later, 
NGF was washed out, and the cells were fed with 
10 ng/ml NGF or medium alone. Cell viability was 
assessed by MTT assay. (B, left) SHP-1 P rescues 
PC12 cells from NGF withdrawal-induced cell death 
in a manner dependent on TrkA. PC12 cells were 
infected with SHP-1 P, and incubated in the absence 
of serum and NGF. Survival was compared with 
uninfected cells incubated in 50 ng/ml NGF or serum 
(B, right). SHP-1 P will not rescue cells from apoptosis 
when TrkA activity is suppressed. Cells treated as in 
the right panel were maintained in the presence of the 
selective Trk kinase inhibitor K252a (200 nM). Cell 
survival was measured using MTT assay. Neither NGF 
nor SHP-1 P could maintain survival in the absence 
of Trk activity, suggesting that SHP-1 P enhances 
survival by increasing TrkA activity. (C) SHP-1 P 
increases the tyrosine phosphorylation of TrkA in the 
absence of NGF in PC12 cells. Cells cultured in media 
lacking NGF were infected with SHP-1 P at the 
indicated MOIs or treated with 50 ng/ml NGF for 5 min 
( NGF). TrkA was immunoprecipitated with anti-Trk 
and probed in Western blots with anti-pTyr (top). The 
levels of TrkA in each lane were visualized by reprobing 
the blots with anti-TrkA. (D) SHP-1 P increases the 
tyrosine phosphorylation of TrkA in the absence of 
NGF in sympathetic neurons. Neurons were infected 
with various MOIs of Ad SHP-1WT, maintained in 
NGF for 2 d, and withdrawn from NGF. As a control, 
neurons were treated with 50 ng/ml NGF for 5 min. 
Lysates were immunoprecipitated with anti-Trk and 
probed with anti-pTyr. (E and F) SHP-1 P expression 
increases Akt and not MAPK phosphorylation in PC12 
cells in the absence of NGF. (E) Western blot analysis 
with an antibody specific to the phosphorylated, 
activated forms of MAPK1/2 (Erk, top panel) and Akt 
(bottom panel) in PC12 cells infected and treated as in panel D. The blot was reprobed for total Erk1/2 or Akt protein to demonstrate that 
equal amounts of protein were present in each lane. (F) Suppression of endogenous SHP-1 activity by SHP-1 P expression results in sustained 
and elevated NGF-activated TrkA tyrosine phosphorylation. Sympathetic neurons cultured for 5 d in 20 ng/ml NGF were infected with SHP-1 P 
or Ad LacZ at the indicated MOI. 48 h later, NGF was washed out, and the cells were treated with 50 ng/ml NGF for 5 min, 10 min, or 48 h. 
TrkA tyrosine phosphorylation in equivalent amount of protein from cell lysates was assessed by immunoprecipitating with anti-Trk and probing 
in Western blots with anti-pTyr. Phosphorylated TrkA migrates underneath the background band seen in all lanes. Error bars represent the SEM. 
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activation of TrkA. To address this possibility, we infected
sympathetic neurons and PC12 cells with Ad SHP-1
 
 
 
P, and
examined TrkA tyrosine phosphorylation. This experiment
demonstrated that for both PC12 cells (Fig. 8 C) and sym-
pathetic neurons (Fig. 8 D), inhibition of SHP-1 led to
TrkA tyrosine phosphorylation and therefore activation in
the absence of exogenous NGF. To determine whether this
increased basal TrkA activation was the mechanism underly-
ing the SHP-1
 
 
 
P–mediated survival effect, we asked
whether inhibition of SHP-1 still caused PC12 cell survival
in the presence of K252a, a selective pharmacological Trk
inhibitor (Tapley et al., 1992; Fig. 8 B, right). The rationale
for this experiment is that SHP-1
 
 
 
P should no longer in-
duce survival in the presence of K252a if SHP-1 functions
solely to inhibit TrkA. However, if SHP-1 suppresses the ac-
tivity of other survival-promoting receptors than TrkA, then
SHP-1
 
 
 
P should continue to induce survival in the absence
of TrkA activity. As predicted, if SHP-1
 
 
 
P functioned only
via TrkA, MTT assays revealed that K252a treatment com-
pletely blocked SHP-1
 
 
 
P’s ability to increase the survival of
NGF-deprived PC12 cells. In contrast, K252a had no effect
on serum-regulated survival of PC12 cells.
 
Inhibition of endogenous SHP-1 differentially activates 
downstream TrkA signaling pathways in the absence 
of NGF
 
These experiments indicated that endogenous SHP-1 nor-
mally functions to keep basal TrkA activation low, and
thereby to maintain the NGF dependence of PC12 cells and
sympathetic neurons. However, SHP-1
 
 
 
P did not cause
PC12 cells to extend neurites in the presence or absence of
serum (unpublished data), suggesting that in the absence
of NGF, SHP-1 inhibition might only activate a subset of
TrkA signaling pathways. In PC12 cells, survival is an Akt-
dependent process, whereas neurite outgrowth is a MEK/
MAPK-dependent process (Klesse et al., 1999; Kaplan and
Miller, 2000). Therefore, we examined the effect of SHP-
1
 
 P on MAPK1/2 and Akt activity. PC12 cells were in-
fected with Ad SHP-1 P, and the phosphorylation state of
Akt and MAPK1/2 in the absence of NGF was examined in
Western blots with phosphospecific antibodies. SHP-1 P
caused an increase in Akt (Fig. 8 E, bottom panel) but not of
MAPK (Erk1/2) phosphorylation (Fig. 8 E, top panel),
which is consistent with the cell biology data.
Because TrkA forms complexes with and activates SHP-1
after NGF treatment of PC12 cells, we asked whether en-
dogenous SHP-1 plays a role in attenuating TrkA activity in
the continued presence of its NGF ligand. In sympathetic
neurons, TrkA tyrosine phosphorylation is maximal after 5
min of exposure to NGF, with this phosphorylation being
largely attenuated by 48 h, even in the continued presence of
NGF (Belliveau et al., 1997; Fig. 8 F). Suppression of SHP-1
activity after SHP-1 P expression led to sustained and ele-
vated TrkA tyrosine phosphorylation in the continuous
presence of 100 ng/ml NGF, with the levels at 48 h being
similar to those seen at 5 min in neurons infected with Ad
LacZ (Fig. 8 F). These results suggest that, in the presence of
NGF, TrkA activates SHP-1, which in turn functions to at-
tenuate TrkA activity and downstream signaling, thereby
participating in a negative feedback loop.
Sympathetic neuron number is increased 
in the me/me mouse
These experiments using cultured cells indicate that endoge-
nous SHP-1 functions both to keep basal levels of TrkA ac-
tivity low in the absence of NGF and to attenuate TrkA ac-
tivity in the presence of NGF. If SHP-1 plays a similar role
in vivo, then sympathetic neurons in the me/me  mouse,
which is genetically deficient in SHP-1, should have up-reg-
ulated TrkA activity, and should not die appropriately dur-
ing naturally occurring cell death. To test this hypothesis, we
analyzed the number of neurons in SCGs taken from P15
me/me mice; the major period of sympathetic neuron death
occurs in the first few weeks postnatally, and SCG neuron
number decreases from  25,000 at birth to  15,000 at
P15. SCGs from me/me and wt mice were removed and sec-
tioned at 7- m thickness, and neuronal numbers were deter-
mined by counting all neuronal profiles with nucleoli on ev-
ery fourth section, as described by Coggeshall et al. (1984).
Figure 9. The number of sympathetic neurons in the superior 
cervical ganglia (SCG) is increased in the absence of SHP-1 in vivo. 
(A) The number of neurons in the SCG of P15 mice from wild type 
(wt/wt) or that lack SHP-1 (me/me) is shown. Results are expressed as 
the mean   SEM for wt/wt, 15,813   813, n   9; and for me/me, 
21,289   452, n   4. Asterisks indicate values significantly different 
from wt mice of the same age. P   0.05. (B and C) TrkA levels are 
decreased in the SCG of me/me mice during the period of naturally 
occurring cell death at P10 and P15, but not at P3. Naturally occurring 
cell death in the SCG from mice has just commenced at P3, is maximal 
at P10, and is completed at P15. Lysates were prepared from SCGs 
dissected from wt/wt and me/me mice. Western blot analysis was 
performed using anti-TrkA (RTA; B and C, top panels). Equal loading 
of protein was confirmed by reprobing the blot with anti-Erk1/2 or 
antitubulin (B and C, bottom panels).SHP-1 is a TrkA phosphatase | Marsh et al. 1007
This analysis demonstrated a statistically significant increase
of 35% in the relative number of sympathetic neurons in me/
me (21,289   452; n   4) relative to wt mice (15,813  
1033; n   9; Fig. 9 A). Therefore, this analysis suggests that
in vivo, SHP-1 regulates sympathetic neuron apoptosis. To
ascertain whether increased TrkA expression could account
for the increases in neuron number, we determined the levels
of TrkA protein in sympathetic ganglia at P3, soon after the
commencement of naturally occurring cell death, and at P10
and P15, when cell death is maximal or complete. TrkA pro-
tein levels were equivalent in wt and me/me SCG at P3, but
were reduced in the me/me SCG by  50% at P10 and P15
(Fig. 9, B and C). Thus, the increase in neuron number
could not be accounted for by an increase in TrkA expression
level. Due to the low levels of TrkA, we could not assess
TrkA autophosphorylation in me/me SCGs.
Sympathetic neurons from mice lacking SHP-1 require 
less NGF to survive than neurons from wt mice
Because the me/me mice showed increased numbers of sym-
pathetic neurons during development, we predicted that
neurons cultured from these mice should survive better than
wt neurons in the absence of NGF. Neurons from newborn
me/me mice, wt littermates, or wt C3H mice were cultured
in 50 ng/ml NGF for 3 d, the NGF was washed away, and
the cells were incubated in 0, 5, or 15 ng/ml NGF. Sympa-
thetic neuron survival is optimal in 15 ng/ml NGF and half-
maximal in 5 ng/ml NGF (Belliveau et al., 1997). Sympa-
thetic neurons from the me/me mice survived much better
than wt neurons in both 5 ng/ml NGF (Fig. 10 A, dashed
lines; and Fig. 10 C) and NGF-deprived conditions (Fig. 10
B). Both me/me and wt neurons survived to similar extents
in optimal (15 ng/ml) NGF (Fig. 10 A, solid lines). Thus,
neurons lacking SHP-1 survive in suboptimal amounts of
NGF, consistent with increased TrkA activity in these cells.
Discussion
In this work, we examined the role of the SHP-1 pTyr phos-
phatase in neurotrophin-mediated cell survival and signal
transduction. Our results indicate that SHP-1 is a TrkA
phosphatase in PC12 cells and in sympathetic neurons in
culture and in vivo, and that it functions to ensure low levels
of basal TrkA activation and to attenuate long-term TrkA
signaling in the presence of NGF. These conclusions are
supported by four findings. First, we show that SHP-1 de-
phosphorylated TrkA in vivo and in vitro, and that dephos-
phorylation was predominantly at sites that controlled TrkA
activity (Y674 and Y675). Second, overexpression of SHP-1
in sympathetic neurons and PC12 cells resulted in apoptosis
as a consequence of TrkA dephosphorylation. Third, inhibi-
tion of endogenous SHP-1 activity was sufficient to support
NGF-independent neuronal survival as a consequence of en-
hanced basal TrkA phosphorylation and downstream Akt
activation. Inhibition of endogenous SHP-1 also led to sus-
tained and elevated TrkA activation in the presence of NGF.
Fourth, sympathetic neuron number was higher in mice ge-
netically deficient in SHP-1, presumably as a consequence of
enhanced TrkA activation during the period of naturally oc-
curring neuronal death; neurons from these mice survived in
limiting amounts of NGF. Together, these results argue that
SHP-1 is a key negative regulator of TrkA-initiated signal
transduction, and that it mediates this negative regulation
largely at the level of the TrkA receptor. Such regulation is
critical for maintaining the trophic factor dependence of at
least one population of neurons during the naturally occur-
ring cell death period, a dependence that is essential for es-
tablishing appropriate neuronal connectivity.
How does SHP-1 regulate TrkA activity? We propose that
SHP-1 regulates both basal and NGF-stimulated TrkA ac-
tivity. Because inhibition of endogenous SHP-1 stimulates
Figure 10. Sympathetic neurons from mice lacking SHP-1 require 
less NGF to survive than neurons from wt mice. (A) me/me neurons 
survive better than wt neurons in suboptimal amounts of NGF. 
Neurons from newborn me/me mice (open diamonds) or wt mice 
(closed triangles) were cultured in 50 ng/ml NGF for 3 d. The NGF 
was washed away, and the neurons were placed in suboptimal 
(5 ng/ml) NGF (dashed lines) or optimal (15 ng/ml) NGF (solid lines) 
for survival. The percentage of surviving neurons was determined 
by counting phase-bright (live) cells in preselected randomly chosen 
fields. Results were normalized such that the number of neurons 
at the time of NGF withdrawal was 100% (0 h). The me/me and wt 
data were from two separate experiments. (B) me/me neurons survive 
better than wt neurons in the absence of NGF. Percentage of survival 
of neurons from me/me (open diamonds) or wt (closed triangles) 
mice established in NGF for 5 d, and then withdrawn completely 
from NGF (0 h). (C) me/me neurons survive better than wt neurons 
in suboptimal NGF. Percentage of survival of me/me (open diamonds) 
and wt (closed triangles) neurons switched into 5 ng/ml NGF. The 
experiments in A–C represent three separate experiments using 
neurons from litters obtained at different times.1008 The Journal of Cell Biology | Volume 163, Number 5, 2003
the NGF-independent phosphorylation of TrkA, SHP-1 can
regulate the basal, nonliganded activity of TrkA. TrkA activ-
ity, in the absence of NGF, is thus normally controlled and
suppressed by SHP-1 activity. In the presence of NGF,
TrkA is efficiently dimerized and hyperactivated, and TrkA
tyrosine kinase activity predominates over basal SHP-1 ty-
rosine phosphatase activity. The enhanced TrkA activity
results in receptor transphosphorylation, followed by re-
cruitment of cytoplasmic signaling proteins to TrkA trans-
phosphorylation sites, and TrkA-induced tyrosine phos-
phorylation of these substrates that in turn stimulates
survival and growth pathways. However, SHP-1 is also re-
cruited to and stimulated by NGF-bound TrkA, resulting in
an increase in SHP-1 tyrosine phosphatase activity. The in-
crease in SHP-1 tyrosine phosphatase activity would result
in an attenuation of TrkA activity. Thus, we propose a
model whereby SHP-1 either directly or indirectly associates
with TrkA, resulting in an increase in SHP-1 activity fol-
lowed by dephosphorylation of TrkA at the Y674 and Y675
sites; a similar mechanism is used by the tyrosine phos-
phatase PTP1B to regulate the insulin receptor (Salmeen et
al., 2000). The dephosphorylation of these sites results in
decreased TrkA biochemical and biological activity (Cun-
ningham et al., 1997) and subsequent decreased activation
of NGF-signaling proteins. Therefore, we suggest that SHP-1
has two functions: (1) to keep TrkA in an “off” state in the
absence of ligand, and (2) to modulate TrkA activity after
dimerization and activation of TrkA by NGF.
What is the role of SHP-1 during sympathetic neuron de-
velopment? We propose that SHP-1 has two functions: (1)
to control TrkA activity in the absence of NGF, and (2) to
“fine-tune” TrkA-mediated survival signals in the presence
of NGF. Correct neuron number during sympathetic devel-
opment is dependent on the functional interplay of TrkA-
induced survival signals and p75
NTR-induced apoptotic sig-
nals (Kaplan and Miller, 2000; Majdan et al., 2001). Mice
deficient in TrkA lack most sympathetic neurons, whereas
mice deficient in p75
NTR have twice the number of sympa-
thetic neurons per ganglia in the SCG at P20. me/me mice
that lack SHP-1 have 35% more neurons than wt mice (Fig.
9 A), indicating that SHP-1 functions during development
to either suppress TrkA activity or the activity of other apop-
totic signals. On the basis of our work in cultured SCG neu-
rons, we favor the former hypothesis. In particular, we pro-
pose that SHP-1 is essential to keep TrkA off in neurons
that have not contacted the correct targets and/or are late ar-
riving, and subsequently, have not sequestered sufficient lev-
els of NGF. Any basal TrkA activation in these neurons
would serve to undermine the biological purpose of the cell
death period, which is to ensure that only those neurons that
are appropriately connected are maintained. Moreover, even
in neurons that have sequestered limited NGF, SHP-1 regu-
lation of TrkA signaling may well serve to regulate the pre-
cise balance between “positive” TrkA and “negative” p75
NTR
signaling, a balance that is essential for establishment of ap-
propriate neuron numbers.
Until recently, SHP-1 expression was largely thought to
be restricted to the hematopoietic system. However, recent
studies have demonstrated that SHP-1 is expressed through-
out the central nervous system in both neurons (Jena et al.,
1997; Horvat et al., 2001) and glia (Massa et al., 2000).
SHP-1 plays a key role in oligodendrocyte and glial develop-
ment, as me/me mice display decreased numbers of central
nervous system glia and dysmyelination (Massa et al., 2000;
Wishcamper et al., 2001). Together, these observations sug-
gest an important role for SHP-1 in the development and
maintenance of the nervous system, a role that we propose is
mediated at least partially via regulation of the TrkA neu-
rotrophin receptor.
Materials and methods
Cells, growth factors, and antibodies
PC12 cells (clone 6-24) and Sf9 insect cells were grown as described pre-
viously (Kaplan et al., 1990; Hempstead et al., 1992). The antibodies used
were as follows: pTyr (4G10) and PLC- 1 monoclonal, and p75
NTR, XIAP,
Akt, and SHP-1 polyclonal antibodies (all from Upstate Biotechnology);
SHP-1 monoclonal (Transduction Laboratories); MAPK monoclonal (Santa
Cruz Biotechnology, Inc.); phosphospecific Akt and phosphospecific c-jun
(Cell Signaling Technology); phosphospecific MAPK (Promega); Bim/Bod
polyclonal (StressGen Biotechnologies); and anti-pan Trk 203 (Hempstead
et al., 1992). The phosphospecific TrkA (Tyr490; 674/675) antibodies were
a gift from R. Segal (Harvard University, Cambridge, MA) or were pur-
chased from Cell Signaling Technology. Anti-TrkA RTA was a gift from L.
Reichardt (University of California, San Francisco, San Francisco, CA).
NGF was obtained from Cedarlane Labs, Ltd.
SCG neuronal cultures
Mass cultures of pure sympathetic neurons derived from the SCG of P1 rats
(Sprague-Dawley) or me/me mice were prepared and cultured as de-
scribed previously (Ma et al., 1992; Bamji et al., 1998).
Expression of recombinant TrkA in Sf9 cells
TrkA association assays were performed as described previously (Kaplan et
al., 1990; Stephens et al., 1994) with the following modifications. Wild-
type and phosphorylation site mutant human TrkA proteins (Stephens et
al., 1994) immunoprecipitated from Sf9 cells and autophosphorylated in
vitro were resuspended in 1 ml of lysate prepared from 10
7 PC12 cells
lysed in NP-40 lysis buffer. The immune complexes were incubated with
the lysate for 3 h at 4 C and washed three times with NP-40 lysis buffer
and once with 10 mM Tris, pH 7.4.
TrkA dephosphorylation assays
Sf9 insect cells infected with SHP-1, SHP-2, or TrkA baculoviruses for 48 h
were lysed in NP-40 lysis buffer, and SHP or TrkA proteins were immuno-
precipitated. TrkA immunoprecipitates were washed once with RIPA,
twice with NP-40 lysis buffer, and once with phosphatase buffer (25 mM
Hepes, pH 7.3, 5 mM EDTA, and 10 mM DTT). Washed TrkA immunopre-
cipitates were incubated for 30 min at 30 C in phosphatase buffer contain-
ing 5  Ci  -[
32P]ATP (5  M ATP final) per reaction. SHP immunoprecipi-
tates were washed once with RIPA, twice with NP-40 lysis buffer, and
once with phosphatase buffer. To detect TrkA dephosphorylation, TrkA
and SHP immunoprecipitates were incubated together for 30 min at 30 C.
The reaction was stopped with Laemmli SDS sample buffer and boiled for
5 min.
Recombinant adenoviruses and viral infections
Replication-defective recombinant Ad SHP-1 WT and  P were prepared
and purified as described previously (Slack et al., 1996; Mazzoni et al.,
1999). Recombinant adenoviruses were amplified and purified on CsCl
gradients and titered by plaque assay. GFP (Aegera Therapeutics Inc.) or
Escherichia coli  -galactosidase (LacZ)–expressing recombinant adenovi-
ruses (provided by F. Graham, McMaster University, Hamilton, ON) were
prepared in the same backbone as the SHP-1 adenoviruses. Viral infec-
tions of sympathetic neurons were performed as described previously
(Mazzoni et al., 1999; Wartiovaara et al., 2002). For PC12 infections, cells
plated on poly-L-lysine were infected with adenoviruses for 48 h.
Immunoprecipitation, immunoblotting,
and immunocytochemistry
Cells were treated with NGF, lysates were prepared, and immunoprecipi-
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(Kaplan et al., 1991; Vambutas et al., 1995; Mazzoni et al., 1999). Lysates
were prepared from normal and me/me SCGs as follows. Freshly dissected
ganglia were homogenized in 100  l of lysis buffer (Kaplan et al., 1991),
transferred to microfuge tubes, rocked gently at 4 C for 30 min, and micro-
centrifuged at 13,000 rpm for 10 min at 4 C. Immunoprecipitations and
Western blots were performed as described by Majdan et al. (2001).
Immunocytochemistry
Fluorescence immunocytochemistry was performed essentially as de-
scribed previously (Wartiovaara et al., 2002). Cells were double labeled
with a polyclonal antibody to neurofilament (1:200; Chemicon) and an
mAb to SHP-1 (1:50; Transduction Laboratories). All the secondary anti-
bodies were obtained from Alexa (goat   Rb Alexa-488 and goat   ms Al-
exa-555, both 1:1,000; Molecular Probes, Inc.). The pictures were taken
using a digital camera (model Retiga Exi; Q-Imaging) mounted directly on
a microscope (model Axioplan 2; Carl Zeiss MicroImaging, Inc.) in a room
with a temperature between 21 and 24 C and with an air objective (model
Plan Neofluor, 20 /0,5; Carl Zeiss MicroImaging, Inc.). The acquisition
software used was Northern Eclipse, and the pictures were assembled in
Adobe Photoshop.
Cell survival assays and analysis of the me/me mice
Survival assays were performed 72 h after NGF withdrawal as described
previously using MTT (Slack et al., 1996), TUNEL (Wartiovaara et al.,
2002), or by counting phase-bright cells. Survival assays with me/me SCG
neurons were performed by counting phase-bright (live) cells in pre-
marked, randomly selected fields at 24-h intervals. The same fields were
followed for the entire experiment with five to seven fields counted per
well (30–300 cells/field). The percentage of survival was calculated by di-
viding the number of phase-bright cells remaining at each time point by
the number of phase-bright cells at 0 h. Control neurons used for these ex-
periments were obtained from either wt littermate or wt C3H mice. The
number of sympathetic neurons per ganglia of the me/me was determined
as described previously (Bamji et al., 1998).
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